Substance / Medication

Perazine

Overview

Active Ingredient
perazine
RxNorm CUI
8042

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Meta-Chlorophenylpiperazine-Induced Behavioral Changes in Obsessive-Compulsive Disorder Research: A Systematic Review of Rodent Studies.
da Silva Jéssica Fernandes, Taguchi Leticia Mitsuko, Leite Erinete da Silva et al. · Neuroscience · 2022
PMID: 36332691Meta-Analysis
The Efficacy and Safety of Prochlorperazine in Patients With Acute Migraine: A Systematic Review and Meta-Analysis.
Golikhatir Iraj, Cheraghmakani Hamed, Bozorgi Farzad et al. · Headache · 2019
PMID: 30990883Meta-Analysis
The Safety of Prochlorperazine in Children: A Systematic Review and Meta-Analysis.
Lau Moon Lin Melissa, Robinson Paula D, Flank Jacqueline et al. · Drug Saf · 2016
PMID: 26884326Meta-Analysis
Perazine for schizophrenia.
Leucht Stefan, Helfer Bartosz, Hartung Benno · Cochrane Database Syst Rev · 2014
PMID: 24425538Meta-AnalysisFull text (PMC)
Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia.
Tardy Magdolna, Dold Markus, Engel Rolf R et al. · Cochrane Database Syst Rev · 2014
PMID: 25003310Meta-AnalysisFull text (PMC)
Trifluoperazine versus placebo for schizophrenia.
Koch Kai, Mansi Kamel, Haynes Euan et al. · Cochrane Database Syst Rev · 2014
PMID: 24414883Meta-AnalysisFull text (PMC)
Perazine for schizophrenia.
Leucht S, Hartung B · Cochrane Database Syst Rev · 2006
PMID: 16625562Meta-Analysis
Trifluoperazine for schizophrenia.
Marques L O, Lima M S, Soares B G O · Cochrane Database Syst Rev · 2004
PMID: 14974020Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Perazine (substance)
SNOMED CT
25002001
UMLS CUI
C0030969
RxNorm CUI
8042

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.